{
    "title": "109_s2255",
    "content": "The Act titled \"Medicare Drug Formulary Protection Act\" allows for the removal of covered Part D drugs from the prescription drug plan formulary. The Medicare Drug Formulary Protection Act prohibits the removal of covered Part D drugs from the prescription drug plan formulary starting in 2006. Starting in 2006, the PDP sponsor of a prescription drug plan cannot remove a covered Part D drug from the plan formulary or impose restrictions on its coverage, except at the beginning of each plan year or as permitted by the Secretary for new therapeutic uses or newly covered drugs. Starting in 2006, the PDP sponsor of a prescription drug plan cannot remove a covered Part D drug from the plan formulary or impose restrictions on its coverage, except at the beginning of each plan year or as permitted by the Secretary for new therapeutic uses or newly covered drugs. For newly enrolled individuals, the PDP sponsor may not remove a covered Part D drug from the plan. For individuals enrolling in a prescription drug plan after the enactment date, the PDP sponsor cannot remove a covered Part D drug or impose restrictions on its coverage until December 31 of the enrollment year. The PDP sponsor cannot remove a covered Part D drug or impose restrictions on its coverage for individuals enrolling in a prescription drug plan after the enactment date until December 31 of the enrollment year, with exceptions for new therapeutic uses and newly covered drugs. Exceptions to the limitation on removing covered Part D drugs include brand name drugs with generic alternatives approved under section 505(j) of the Food and Drug Cosmetic Act, and brand name drugs going off-patent during the restricted period. During a restricted period, limitations on removal or change in the formulary apply to brand name drugs that go off-patent, drugs with FDA-imposed restrictions, and drugs deemed ineffective. Notice of removal must be provided under application. During a restricted period, limitations on removal or change in the formulary apply to brand name drugs that go off-patent, drugs with FDA-imposed restrictions, and drugs deemed ineffective. Notice of removal must be provided under application to the Secretary, affected enrollees, physicians, pharmacies, and pharmacists. Each PDP sponsor must provide an annual notice of changes in formulary and coverage restrictions to enrollees during the coordinated election period. Each PDP sponsor must provide enrollees with a notice of any changes in formulary or coverage restrictions during the annual coordinated election period for a plan year. The amendment applies to annual coordinated election periods after the enactment of the Act."
}